Total bookings and revenue growth accelerated to 14% y/y in Q3, fueled by robust new cohort behavior and Base44 ...

The MarketWatch News Department was not involved in the creation of this content.-- Omlyclo(TM) (omalizumab) is the first and only omalizumab biosimilar approved in Europe -- Omly ...

Antimicrobial resistance (AMR) causes over 35,000 deaths annually in the EU/EEA and is projected to result in 1.91 million ...

BEIJING, CHINA - Media OutReach Newswire - 18 November 2025 - On November 12, 2025, the thematic investment promotion event "Synergy Between Beijing and Hong Kong, Connecting the World – Towards a ...

Navios Maritime Partners L.P. Common Units ( NMM) Q3 2025 Earnings Call November 18, 2025 8:30 AM EST ...

The Office of Undergraduate Research organizes the Symposium of Student Scholars twice per year, offering students a unique ...

Net Loan-To-Value (LTV) -- 34.5% with a target net LTV range of 20%-25% stated by management. Available Liquidity -- $412 million reported as of quarter-end. Contracted Revenue Backlog -- $3.7 billion ...

Research and development expenses for the three months ended September 30, 2025 were approximately $607,000, compared to $1.4 million for the same period in 2024. General and administrative expenses ...

In particular, Konagurthu says, AI/ML can help sift through a field of drug candidates in which the percentage that are ...

BellRing Brands, Inc. (NYSE:BRBR) (“BellRing”), a holding company operating in the global convenient nutrition category, today reported results for the fourth fiscal ...

In September 2025, the European Commission (EC), together with the Heads of Medicines Agencies (HMA) and the European ...